1 thout replacing the missing values (observed-
cases analysis).
2 ks after drug administration using available
case analysis.
3 ICERs (up to 4.2-fold) in conservative base-
case analysis.
4 patient over 2-year time horizon at the base
case analysis.
5 nd increase precision compared with complete-
case analysis.
6 We did a completed
case analysis.
7 esions was evaluated with a leave-one-out-by-
case analysis.
8 ion in a 30-year-old male was used as a base
case analysis.
9 of the cases were excluded from the complete
case analysis.
10 th a missing covariate to perform a complete
case analysis.
11 tient hospital setting was used for the base-
case analysis.
12 in so-called "complete records" or "complete
case" analysis.
13 In the base-
case analysis,
11,646,000 persons in the US would be scr
14 ared using 4 different missing-data complete-
case analysis,
2 multiple-imputation models, and nearest
15 to handle missing outcome data: 1) complete
case analysis;
2) single imputation; and 3) multiple imp
16 In the base-
case analysis,
all strategies for influenza vaccination
17 In the base
case analysis,
anakinra was the least effective and leas
18 roups was not significant, both for complete
case analysis and multiple imputation analysis.
19 with the level of agreement between complete
case analysis and the true data (ICC = 0.93 and kappa =
20 Results: In the base-
case analysis,
annual combined screening was most effect
21 ant-factor approximation guarantees in worst-
case analysis,
as opposed to the much coarser additive-e
22 The base
case analysis assumed that a hospital with an existing l
23 In the primary (complete-
case) analysis at 144 weeks, 317 (86%) of 367 in the pro
24 Results of Base-
Case Analysis:
At 10 years, scale-back strategies increa
25 A complete-
case analysis based on all 3 SNPs was found to be more p
26 using a structured qualitative method (cross-
case analysis based on predefined categories and develop
27 In the base-
case analysis BOC-RVR and TVR-IL28B strategies were the
28 Results of Base-
Case Analysis:
By reducing incidence and severity of her
29 Results of Base-
Case Analysis:
Clinically important HTEs could explain d
30 In the base-
case analysis,
compared with no additional intervention,
31 In 1 base-
case analysis,
compliance was assumed to be 60% with the
32 In the base-
case analysis,
costs from the French National Insurance
33 In the observed
case analysis,
cough frequency was reduced by 75% when p
34 In the base-
case analysis dose-adjusted sorafenib was the most effec
35 In case-
case analysis,
EBV(+) disease was significantly associat
36 This retrospective
case analysis evaluated the feasibility and activity of
37 Results of Base-
Case Analysis:
FIT screening without surveillance reduce
38 Base-
case analysis focused on patients with average-risk brea
39 lity ratios were estimated based on complete
case analysis for the base case analysis, where only pat
40 In the base-
case analysis for the voluntary screening program, overa
41 Base
case analysis found DSAEK to be less costly compared wit
42 justed life year was pound56,811 in the base
case analysis from a National Health Service perspective
43 We performed the base-
case analysis from the societal perspective with a willi
44 In the base-
case analysis,
if CTC were used as the primary modality
45 In the base-
case analysis,
if in-hospital advance care planning and
46 Results of Base-
Case Analysis:
Immediate access to OAT for all treatment
47 The base
case analysis in a cohort of 1763 patients undergoing ca
48 In a base-
case analysis in which compliance with screening and fol
49 The base-
case analysis included a hypothetical cohort of 60-year-
50 A case-by-
case analysis indicated that misses and false-positive r
51 Results of Base-
Case Analysis:
Individualized control saved $13 547 per
52 The reference
case analysis is conducted from the societal perspective
53 s to deal with them are rare, and a complete-
case analysis is the norm.
54 Besides the complete
case analysis,
multiple imputation analysis was performe
55 In a multivariable complete
case analysis (
n = 371 [92.9%]) adjusting for potential
56 In an exact-matched
case analysis (
n = 38), median survival time for RSR13 p
57 in the extractive industries, and empirical
case analysis of 50 projects worldwide, this research re
58 This is the largest
case analysis of MTT and one of the few to document an i
59 Retrospective
case analysis of patients with surgical repair of open g
60 be strongly regulated, as well as by case-by-
case analysis of the genes on the basis of expert domain
61 A complete
case analysis of the outcome of kidney-only transplants
62 ephrotic syndrome requires a careful case-by-
case analysis of the risks for thromboembolic events bal
63 tron-exon splice regions of KEL and, in some
cases, analysis of mRNA transcripts and expression of mu
64 cluding patients with missing data (complete
case analysis),
or (3) excluding the predictor with miss
65 Results of Base-
Case Analysis:
PrEP+screen+ART dominates other strategie
66 This
case analysis raises several concerns: risks of vermicul
67 Individual
case analysis revealed that subtle changes in language w
68 The base
case analysis showed acupuncture to be marginally more e
69 A case-
case analysis showed association of infection with the o
70 Worst-
case analysis suggests that THA remains minimally cost-e
71 hile supporting GWAS validation and clinical
case analysis tasks.
72 factors on survival, we assumed in our base-
case analysis that 50 percent of the gains were due to m
73 In the complete
case analysis the absolute risk difference for the occur
74 In the base
case analysis,
the addition of necitumumab to the treatm
75 For the Italian base-
case analysis,
the cost-effective ICER obtained using po
76 For the base
case analysis,
the expected cost of providing stress ulc
77 For the base-
case analysis,
the incremental cost per quality-adjusted
78 In the base-
case analysis,
the net cost per DALY averted was $833 co
79 In the base-
case analysis,
the Newhints intervention cost a mean of
80 r recommendations constituting the reference
case analysis,
the set of practices developed to guide C
81 Results of Base-
Case Analysis:
The sacubitril-valsartan group experience
82 Results of Base-
Case Analysis:
The within-trial analysis found that etan
83 se outcomes, one can carry out either a case-
case analysis to investigate etiologic heterogeneity or
84 In the base-
case analysis,
treatment of CD patients with a steroid-i
85 In the base-
case analysis,
use of antiseptic-impregnated catheters r
86 er a 12-year period METHODS: A retrospective
case analysis using a glaucoma electronic patient record
87 value is estimated by performing a complete-
case analysis using a random-effects model that includes
88 tal cost per depression-free day in the base-
case analysis was $10 (95% confidence interval, -$13 to
89 The base-
case analysis was a cohort of 50-year-old patients.
90 To eliminate cost outliers, a best-
case analysis was performed by eliminating 50% of patien
91 The base-
case analysis was performed for a hypothetical cohort of
92 In our base-
case analysis,
we assumed that H pylori treatment preven
93 In the base
case analysis,
we assumed that the sensitivity and speci
94 based on complete case analysis for the base
case analysis,
where only patients with available EQ-5D
95 In the base
case analysis with a prevalence of stones of 9%, IOUS wa
96 Complete
case analysis with covariate adjustment and multiple imp
97 Hence, complete
case analysis with covariate adjustment can and should b
98 Estimates obtained by complete
case analysis with covariate adjustment were unbiased as
99 In our base-
case analysis with either outcome, MTX continuation, cyc
100 ethods reduced bias compared with a complete
case analysis without covariate adjustment.